221 related articles for article (PubMed ID: 22370968)
1. HIV therapies and the kidney: some good, some not so good?
Ryom L; Mocroft A; Lundgren J
Curr HIV/AIDS Rep; 2012 Jun; 9(2):111-20. PubMed ID: 22370968
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Tanaka H; Arai M; Tomoda Y; Wada T; Yago K; Satoh M
J Pharm Pharm Sci; 2013; 16(3):405-13. PubMed ID: 24021289
[TBL] [Abstract][Full Text] [Related]
3. Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.
Ryom L; Mocroft A; Kirk O; Worm SW; Kamara DA; Reiss P; Ross M; Fux CA; Morlat P; Moranne O; Smith C; Lundgren JD;
J Infect Dis; 2013 May; 207(9):1359-69. PubMed ID: 23382571
[TBL] [Abstract][Full Text] [Related]
4. Effect of tenofovir on renal glomerular and tubular function.
Fux CA; Christen A; Zgraggen S; Mohaupt MG; Furrer H
AIDS; 2007 Jul; 21(11):1483-5. PubMed ID: 17589197
[TBL] [Abstract][Full Text] [Related]
5. Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Gérard L; Chazallon C; Taburet AM; Girard PM; Aboulker JP; Piketty C
Antivir Ther; 2007; 12(1):31-9. PubMed ID: 17503745
[TBL] [Abstract][Full Text] [Related]
6. Renal safety of tenofovir disoproxil fumarate.
Sax PE; Gallant JE; Klotman PE
AIDS Read; 2007 Feb; 17(2):90-2, 99-104, C3. PubMed ID: 17323508
[TBL] [Abstract][Full Text] [Related]
7. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
Nelson MR; Katlama C; Montaner JS; Cooper DA; Gazzard B; Clotet B; Lazzarin A; Schewe K; Lange J; Wyatt C; Curtis S; Chen SS; Smith S; Bischofberger N; Rooney JF
AIDS; 2007 Jun; 21(10):1273-81. PubMed ID: 17545703
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of tenofovir due to nephrotoxicity: insight into 12 years of clinical practice.
Matłosz B; Kowalska JD; Bąkowska E; Firląg-Burkacka E; Vassilenko A; Horban A
Przegl Epidemiol; 2019; 73(2):249-255. PubMed ID: 31385682
[TBL] [Abstract][Full Text] [Related]
9. Nephrotoxicity as a complication of antiretroviral therapy.
Valle R; Haragsim L
Adv Chronic Kidney Dis; 2006 Jul; 13(3):314-9. PubMed ID: 16815236
[TBL] [Abstract][Full Text] [Related]
10. [Nephrotoxicity of antiretrovirals other than tenofovir].
Loens C; Amet S; Isnard-Bagnis C; Deray G; Tourret J
Nephrol Ther; 2018 Feb; 14(1):55-66. PubMed ID: 29500080
[TBL] [Abstract][Full Text] [Related]
11. Renal toxicity of long-term therapy with tenofovir in HIV-infected patients.
Monteagudo-Chu MO; Chang MH; Fung HB; Bräu N
J Pharm Pract; 2012 Oct; 25(5):552-9. PubMed ID: 22551561
[TBL] [Abstract][Full Text] [Related]
12. Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Young J; Schäfer J; Fux CA; Furrer H; Bernasconi E; Vernazza P; Calmy A; Cavassini M; Weber R; Battegay M; Bucher HC;
AIDS; 2012 Mar; 26(5):567-75. PubMed ID: 22398568
[TBL] [Abstract][Full Text] [Related]
13. Tenofovir-associated decline in renal function.
Crane HM; Kestenbaum B; Harrington RD; Kitahata MM
J Infect Dis; 2008 Sep; 198(6):937; author reply 937-8. PubMed ID: 18721062
[No Abstract] [Full Text] [Related]
14. Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
Madden E; Lee G; Kotler DP; Wanke C; Lewis CE; Tracy R; Heymsfield S; Shlipak MG; Bacchetti P; Scherzer R; Grunfeld C
AIDS; 2008 Mar; 22(6):707-15. PubMed ID: 18356600
[TBL] [Abstract][Full Text] [Related]
15. Progression of renal impairment under therapy with tenofovir.
Jülg BD; Bogner JR; Crispin A; Goebel FD
AIDS; 2005 Aug; 19(12):1332-3. PubMed ID: 16052093
[No Abstract] [Full Text] [Related]
16. Antiretroviral therapy and the kidney.
Wyatt CM
Top Antivir Med; 2014; 22(3):655-8. PubMed ID: 25101531
[TBL] [Abstract][Full Text] [Related]
17. Chronic renal failure among HIV-1-infected patients.
Mocroft A; Kirk O; Gatell J; Reiss P; Gargalianos P; Zilmer K; Beniowski M; Viard JP; Staszewski S; Lundgren JD
AIDS; 2007 May; 21(9):1119-27. PubMed ID: 17502722
[TBL] [Abstract][Full Text] [Related]
18. Improvement in chronic renal impairment following the discontinuation of tenofovir in two HIV-infected patients.
Gracey D; Post J; MacLeod C; McKenzie P
Nephrology (Carlton); 2011 May; 16(4):453-5. PubMed ID: 21518120
[No Abstract] [Full Text] [Related]
19. Hypokalemia in HIV patients on tenofovir.
Cirino CM; Kan VL
AIDS; 2006 Aug; 20(12):1671-3. PubMed ID: 16868451
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
